CHINA SXT PHARMACEUTICALS-A (SXTC) Fundamental Analysis & Valuation

NASDAQ:SXTC • VGG2161P1650

Current stock price

2.1 USD
-0.02 (-0.94%)
At close:
2 USD
-0.1 (-4.76%)
After Hours:

This SXTC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SXTC Profitability Analysis

1.1 Basic Checks

  • In the past year SXTC has reported negative net income.
  • SXTC had a negative operating cash flow in the past year.
  • SXTC had negative earnings in each of the past 5 years.
  • In the past 5 years SXTC reported 4 times negative operating cash flow.
SXTC Yearly Net Income VS EBIT VS OCF VS FCFSXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2M -4M -6M -8M -10M

1.2 Ratios

  • SXTC has a Return On Assets (-33.66%) which is comparable to the rest of the industry.
  • SXTC has a Return On Equity (-43.84%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -33.66%
ROE -43.84%
ROIC N/A
ROA(3y)-16.24%
ROA(5y)-14.76%
ROE(3y)-28%
ROE(5y)-27.24%
ROIC(3y)N/A
ROIC(5y)N/A
SXTC Yearly ROA, ROE, ROICSXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

1.3 Margins

  • Looking at the Gross Margin, with a value of 21.74%, SXTC is in line with its industry, outperforming 52.88% of the companies in the same industry.
  • SXTC's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SXTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-16.61%
SXTC Yearly Profit, Operating, Gross MarginsSXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. SXTC Health Analysis

2.1 Basic Checks

  • SXTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SXTC has more shares outstanding
  • Compared to 5 years ago, SXTC has more shares outstanding
  • The debt/assets ratio for SXTC has been reduced compared to a year ago.
SXTC Yearly Shares OutstandingSXTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20K 40K 60K 80K
SXTC Yearly Total Debt VS Total AssetsSXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • SXTC has an Altman-Z score of -1.29. This is a bad value and indicates that SXTC is not financially healthy and even has some risk of bankruptcy.
  • SXTC has a Altman-Z score (-1.29) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.05 indicates that SXTC is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.05, SXTC is in line with its industry, outperforming 50.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -1.29
ROIC/WACCN/A
WACC7.52%
SXTC Yearly LT Debt VS Equity VS FCFSXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M 15M

2.3 Liquidity

  • SXTC has a Current Ratio of 4.37. This indicates that SXTC is financially healthy and has no problem in meeting its short term obligations.
  • SXTC has a Current ratio of 4.37. This is in the better half of the industry: SXTC outperforms 60.21% of its industry peers.
  • A Quick Ratio of 4.24 indicates that SXTC has no problem at all paying its short term obligations.
  • SXTC's Quick ratio of 4.24 is fine compared to the rest of the industry. SXTC outperforms 61.26% of its industry peers.
Industry RankSector Rank
Current Ratio 4.37
Quick Ratio 4.24
SXTC Yearly Current Assets VS Current LiabilitesSXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SXTC Growth Analysis

3.1 Past

  • SXTC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -102.65%.
  • Looking at the last year, SXTC shows a very negative growth in Revenue. The Revenue has decreased by -15.42% in the last year.
  • Measured over the past years, SXTC shows a very negative growth in Revenue. The Revenue has been decreasing by -19.53% on average per year.
EPS 1Y (TTM)-102.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.24%
Revenue 1Y (TTM)-15.42%
Revenue growth 3Y-12.51%
Revenue growth 5Y-19.53%
Sales Q2Q%-24.46%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SXTC Yearly Revenue VS EstimatesSXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

Find the best growth stocksShow best growing peers

0

4. SXTC Valuation Analysis

4.1 Price/Earnings Ratio

  • SXTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTC Price Earnings VS Forward Price EarningsSXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTC Per share dataSXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SXTC Dividend Analysis

5.1 Amount

  • No dividends for SXTC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SXTC Fundamentals: All Metrics, Ratios and Statistics

CHINA SXT PHARMACEUTICALS-A

NASDAQ:SXTC (4/24/2026, 2:59:58 PM)

After market: 2 -0.1 (-4.76%)

2.1

-0.02 (-0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-31
Earnings (Next)N/A
Inst Owners0.23%
Inst Owner Change136.35%
Ins Owners28.54%
Ins Owner ChangeN/A
Market Cap6.22M
Revenue(TTM)1.54M
Net Income(TTM)-8.87M
Analysts0
Price TargetN/A
Short Float %9.39%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.04
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB 0.31
EV/EBITDA N/A
EPS(TTM)-161.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0.52
BVpS6.84
TBVpS6.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -33.66%
ROE -43.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.74%
FCFM N/A
ROA(3y)-16.24%
ROA(5y)-14.76%
ROE(3y)-28%
ROE(5y)-27.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-16.61%
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.37
Quick Ratio 4.24
Altman-Z -1.29
F-Score3
WACC7.52%
ROIC/WACCN/A
Cap/Depr(3y)11.31%
Cap/Depr(5y)15.68%
Cap/Sales(3y)1.35%
Cap/Sales(5y)1.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-102.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.24%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.42%
Revenue growth 3Y-12.51%
Revenue growth 5Y-19.53%
Sales Q2Q%-24.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-235.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1614.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2391.55%
OCF growth 3YN/A
OCF growth 5YN/A

CHINA SXT PHARMACEUTICALS-A / SXTC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CHINA SXT PHARMACEUTICALS-A (SXTC) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SXTC.


What is the valuation status for SXTC stock?

ChartMill assigns a valuation rating of 0 / 10 to CHINA SXT PHARMACEUTICALS-A (SXTC). This can be considered as Overvalued.


Can you provide the profitability details for CHINA SXT PHARMACEUTICALS-A?

CHINA SXT PHARMACEUTICALS-A (SXTC) has a profitability rating of 1 / 10.


What is the financial health of CHINA SXT PHARMACEUTICALS-A (SXTC) stock?

The financial health rating of CHINA SXT PHARMACEUTICALS-A (SXTC) is 4 / 10.